HeartMate 3™ LIS Study (HM 3 LIS)

• ClinicalTrials.gov Identifier: NCT02475460
• Recruitment Status: Completed
• First Posted: June 18, 2015
• Last Update Posted: June 24, 2022
• Sponsor: Abbott Medical Devices
• Collaborator: Thoratec Corporation
• Information provided by (Responsible Party): Abbott Medical Devices

Study Description

Brief Summary:

The purpose of this study is to evaluate a less invasive implantation technique of the HeartMate 3 Left Ventricular Assist System (HM 3 LVAS) in 10 patients.

Condition or disease	Intervention/treatment	Phase
Heart Failure; Cardiovascular Disease	Procedure: Less Invasive Surgery (LIS); Device: HeartMate 3™	Not Applicable

Detailed Description:

This study will evaluate the less invasive implantation technique of the HM 3 LVAS.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 13 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Thoratec Corporation HeartMate 3™ Less Invasive Surgery (LIS) Study
• Study Start Date: May 2015
• Actual Primary Completion Date: January 2016
• Actual Study Completion Date: July 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: HM 3 LIS; All patients implanted with the HM 3 LVAD via less invasive surgical technique	Procedure: Less Invasive Surgery (LIS); Less invasive HM 3 LVAD surgical implant procedure; Device: HeartMate 3™; HM 3 LIS

Outcome Measures

Primary Outcome Measures :

1. Number of survival participants [ Time Frame: 30 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patient or legal representative has signed Informed Consent Form (ICF)
2. Age ≥ 18 years
3. BSA ≥ 1.2 m2
4. NYHA IIIB or IV, or ACC/AHA Stage D
5. LVEF ≤ 25%
6. CI ≤ 2.2 L/min/m2, while not on inotropes (if Patient is treated with inotropes at baseline, this does not apply)

7. Patients must also meet one of the following:

   • On optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond, OR
   • In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on intraaortic balloon pump (IABP) for at least 7 days, OR
   • Inotrope dependent/unable to wean from inotropes OR
   • Listed for transplant
8. Females of child bearing age must agree to use adequate contraception-

Exclusion Criteria:

1. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy
2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the Investigator
3. Existence of ongoing mechanical circulatory support (MCS) other than IABP
4. Positive pregnancy test if of childbearing potential
5. Lactating mothers
6. Presence of mechanical aortic cardiac valve
7. History of any organ transplant
8. Platelet count < 100,000 x 103/L (< 100,000/ml)
9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management
10. History of confirmed, untreated AAA > 5 cm in diameter
11. Presence of an active, uncontrolled infection
12. Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy that the Investigator will require based upon the patients' health status

13. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:

    • An INR ≥ 2.5 not due to anticoagulation therapy
    • Total bilirubin > 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver cirrhosis
    • History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC < 0.7, or FEV1 <50% predicted
    • Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention
    • History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (> 80%) carotid artery stenosis
    • Serum Creatinine ≥ 221umol/L (2.5 mg/dl) or the need for chronic renal replacement therapy
    • Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration
14. Aortic valve regurgitation > grade 1
15. Pre albumin < 150 mg/L, or Albumin < 30g/L (3 g/dL)
16. Planned Bi-VAD support prior to enrollment
17. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia
18. Planned concomitant intra-cardiac cardiac surgery
19. Thrombus formation in the atrium or left ventricle identified by echocardiogram
20. Previous sternotomy or left-sided thoracotomy
21. Participation in any other clinical investigation that is likely to confound study results or affect the study
22. Any condition other than HF that could limit survival to less than 6 months

Contacts and Locations

Locations

Czechia

Institute for Clinical and Experimental Medicine (IKEM)

Prague, Czechia, 4

Germany

Deutsches Herzzentrum Berlin

Berlin, Germany, 13353

Medizinische Hochschule Hannover

Hannover, Germany, 30625

Sponsors and Collaborators

Abbott Medical Devices

Thoratec Corporation

Investigators

• Study Director: Sami Somo; Abbott

More Information

• Responsible Party: Abbott Medical Devices
• ClinicalTrials.gov Identifier: NCT02475460
• Other Study ID Numbers: HeartMate 3 LIS
• First Posted: June 18, 2015
• Last Update Posted: June 24, 2022
• Last Verified: June 2022

Keywords provided by Abbott Medical Devices:

HeartMate 3; LVAS; LVAD; Heart-assist Devices; Advanced; Ventricular Dysfunction; refractory left ventricular; Thoratec Corporation

Additional relevant MeSH terms:

Cardiovascular Diseases